144 related articles for article (PubMed ID: 34821387)
1. Study of the effects of interferon β-1a on hospitalized patients with COVID-19: SBMU Taskforce on the COVIFERON study.
Fallahzadeh M; Pourhoseingholi MA; Boroujeni MG; Besharati S; Mardani M; Shabani M; Shokouhi S; Amirdosara M; Hajiesmaeili M; Gachkar L; Roshan B; Zangi M; Mirmomeni G; Irvani SSN; Alavi Darazam I
J Med Virol; 2022 Apr; 94(4):1488-1493. PubMed ID: 34821387
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of Interferon Beta 1a, compared to Interferon Beta 1b and the usual therapeutic regimen to treat adults with moderate to severe COVID-19: structured summary of a study protocol for a randomized controlled trial.
Irvani SSN; Golmohammadi M; Pourhoseingholi MA; Shokouhi S; Darazam IA
Trials; 2020 Jun; 21(1):473. PubMed ID: 32493468
[TBL] [Abstract][Full Text] [Related]
3. An investigation into the beneficial effects of high-dose interferon beta 1-a, compared to low-dose interferon beta 1-a (the base therapeutic regimen) in moderate to severe COVID-19: A structured summary of a study protocol for a randomized controlled l trial.
Alavi Darazam I; Hatami F; Rabiei MM; Pourhoseingholi MA; Moradi O; Shokouhi S; Hajesmaeili MR; Shabani M; Irvani SSN
Trials; 2020 Oct; 21(1):880. PubMed ID: 33106183
[TBL] [Abstract][Full Text] [Related]
4. A Randomized Clinical Trial of the Efficacy and Safety of Interferon β-1a in Treatment of Severe COVID-19.
Davoudi-Monfared E; Rahmani H; Khalili H; Hajiabdolbaghi M; Salehi M; Abbasian L; Kazemzadeh H; Yekaninejad MS
Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32661006
[TBL] [Abstract][Full Text] [Related]
5. An investigation into the beneficial effects of high-dose interferon beta 1-a, compared to low-dose interferon beta 1-a in severe COVID-19: The COVIFERON II randomized controlled trial.
Alavi Darazam I; Hatami F; Mahdi Rabiei M; Amin Pourhoseingholi M; Shabani M; Shokouhi S; Mardani M; Moradi O; Javandoust Gharehbagh F; Mirtalaee N; Negahban H; Amirdosara M; Zangi M; Hajiesmaeili M; Kazempour M; Shafigh N
Int Immunopharmacol; 2021 Oct; 99():107916. PubMed ID: 34224994
[TBL] [Abstract][Full Text] [Related]
6. Comparing the outcomes of treatment with INF-β 1-a (interferon beta-1a) and IFN-β 1-b (interferon beta-1b) among COVID-19 inpatients.
Seyfi S; Latifi K; Amri Male P; Sadeghi Haddad Zavareh M; Ezoji K; Mohammadnia-Afrozi M
Int Immunopharmacol; 2021 Dec; 101(Pt B):108241. PubMed ID: 34688151
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the efficacy and safety of favipiravir and interferon compared to lopinavir/ritonavir and interferon in moderately ill patients with COVID-19: a structured summary of a study protocol for a randomized controlled trial.
Hassaniazad M; Bazram A; Hassanipour S; Fathalipour M
Trials; 2020 Oct; 21(1):886. PubMed ID: 33109246
[TBL] [Abstract][Full Text] [Related]
8. The efficacy and safety of Ivermectin in patients with mild and moderate COVID-19: A structured summary of a study protocol for a randomized controlled trial.
Hosseini FS; Malektojari A; Ghazizadeh S; Hassaniazad M; Davoodian P; Dadvand H; Nikpoor AR; Nikoofal-Sahlabadi S; Kahoori S; Sepandi M; Hassanipour S; Fathalipour M
Trials; 2021 Jan; 22(1):4. PubMed ID: 33397429
[TBL] [Abstract][Full Text] [Related]
9. An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19.
Ader F; Peiffer-Smadja N; Poissy J; Bouscambert-Duchamp M; Belhadi D; Diallo A; Delmas C; Saillard J; Dechanet A; Mercier N; Dupont A; Alfaiate T; Lescure FX; Raffi F; Goehringer F; Kimmoun A; Jaureguiberry S; Reignier J; Nseir S; Danion F; Clere-Jehl R; Bouiller K; Navellou JC; Tolsma V; Cabié A; Dubost C; Courjon J; Leroy S; Mootien J; Gaci R; Mourvillier B; Faure E; Pourcher V; Gallien S; Launay O; Lacombe K; Lanoix JP; Makinson A; Martin-Blondel G; Bouadma L; Botelho-Nevers E; Gagneux-Brunon A; Epaulard O; Piroth L; Wallet F; Richard JC; Reuter J; Staub T; Lina B; Noret M; Andrejak C; Lê MP; Peytavin G; Hites M; Costagliola D; Yazdanpanah Y; Burdet C; Mentré F;
Clin Microbiol Infect; 2021 Dec; 27(12):1826-1837. PubMed ID: 34048876
[TBL] [Abstract][Full Text] [Related]
10. Antiviral and immunomodulatory interferon-beta in high-risk COVID-19 patients: a structured summary of a study protocol for a randomised controlled trial.
Aricò E; Castiello L; Bracci L; Urbani F; Lombardo F; Bacigalupo I; Ancidoni A; Vanacore N; Falcione A; Reggiani C; Dutti GM; Maglie MG; Papa O; Bartoletti PL; Ozzella G; Bevilacqua N; Nicastri E; Belardelli F; Sconocchia G
Trials; 2021 Sep; 22(1):584. PubMed ID: 34479601
[TBL] [Abstract][Full Text] [Related]
11. Role of interferon therapy in severe COVID-19: the COVIFERON randomized controlled trial.
Alavi Darazam I; Shokouhi S; Pourhoseingholi MA; Naghibi Irvani SS; Mokhtari M; Shabani M; Amirdosara M; Torabinavid P; Golmohammadi M; Hashemi S; Azimi A; Jafarazadeh Maivan MH; Rezaei O; Zali A; Hajiesmaeili M; Shabanpour Dehbsneh H; Hoseyni Kusha A; Taleb Shoushtari M; Khalili N; Soleymaninia A; Gachkar L; Khoshkar A
Sci Rep; 2021 Apr; 11(1):8059. PubMed ID: 33850184
[TBL] [Abstract][Full Text] [Related]
12. Antiviral activity of interferon-based combination therapy in critically ill patients with COVID-19: Preliminary observations.
Gaibani P; Tonetti T; Bartoletti M; Re MC; Viale P; Ranieri VM
J Glob Antimicrob Resist; 2021 Mar; 24():124-126. PubMed ID: 33385588
[No Abstract] [Full Text] [Related]
13. In inpatients with COVID-19, none of remdesivir, hydroxychloroquine, lopinavir, or interferon β-1a differed from standard care for in-hospital mortality.
Zhang R; Mylonakis E
Ann Intern Med; 2021 Feb; 174(2):JC17. PubMed ID: 33524282
[TBL] [Abstract][Full Text] [Related]
14. Interferons and Multiple Sclerosis: Lessons from 25 Years of Clinical and Real-World Experience with Intramuscular Interferon Beta-1a (Avonex).
Cohan SL; Hendin BA; Reder AT; Smoot K; Avila R; Mendoza JP; Weinstock-Guttman B
CNS Drugs; 2021 Jul; 35(7):743-767. PubMed ID: 34228301
[TBL] [Abstract][Full Text] [Related]
15. Impact of early interferon-β treatment on the prognosis of patients with COVID-19 in the first wave: A post hoc analysis from a multicenter cohort.
Salto-Alejandre S; Palacios-Baena ZR; Arribas JR; Berenguer J; Carratalà J; Jarrín I; Ryan P; Miguel-Montero M; Rodríguez-Baño J; Pachón J;
Biomed Pharmacother; 2022 Feb; 146():112572. PubMed ID: 34954640
[TBL] [Abstract][Full Text] [Related]
16. A cluster randomized trial of interferon ß-1a for the reduction of transmission of SARS-Cov-2: protocol for the Containing Coronavirus Disease 19 trial (ConCorD-19).
Iturriaga C; Eiffler N; Aniba R; Ben-Othman R; Perez-Mateluna G; Meyer JKV; Fish EN; Kollmann TR; Severino N; Stick S; Borzutzky A; Perret C; Castro-Rodriguez JA; Garcia-Huidobro D
BMC Infect Dis; 2021 Aug; 21(1):814. PubMed ID: 34388972
[TBL] [Abstract][Full Text] [Related]
17. Clinical Characteristics and Outcomes of 905 COVID-19 Patients Admitted to Imam Khomeini Hospital Complex in the Capital City of Tehran, Iran.
Allameh SF; Nemati S; Ghalehtaki R; Mohammadnejad E; Aghili SM; Khajavirad N; Beigmohammadi MT; Salehi M; Mirfazaelian H; Edalatifard M; Kazemizadeh H; Dehghan Manshadi SA; Hasannezhad M; Amoozadeh L; Radnia M; Khatami SR; Nahvijou A; Seyyedsalehi MS; Rashidian L; Ayoobi Yazdi N; Nasiri Toosi M; Sadeghniiat-Haghighi K; Jafarian A; Yunesian M; Zendehdel K
Arch Iran Med; 2020 Nov; 23(11):766-775. PubMed ID: 33220695
[TBL] [Abstract][Full Text] [Related]
18. Interferon beta 1a versus interferon beta 1a plus ribavirin for the treatment of chronic hepatitis C in Chinese patients: a randomized, placebo-controlled trial.
Han Q; Liu Z; Kang W; Li H; Zhang L; Zhang N
Dig Dis Sci; 2008 Aug; 53(8):2238-45. PubMed ID: 18080763
[TBL] [Abstract][Full Text] [Related]
19. Effect of a genetically engineered interferon-alpha versus traditional interferon-alpha in the treatment of moderate-to-severe COVID-19: a randomised clinical trial.
Li C; Luo F; Liu C; Xiong N; Xu Z; Zhang W; Yang M; Wang Y; Liu D; Yu C; Zeng J; Zhang L; Li D; Liu Y; Feng M; Liu R; Mei J; Deng S; Zeng Z; He Y; Liu H; Shi Z; Duan M; Kang D; Liao J; Li W; Liu L
Ann Med; 2021 Dec; 53(1):391-401. PubMed ID: 33620016
[TBL] [Abstract][Full Text] [Related]
20. Interferon-α2b spray inhalation did not shorten virus shedding time of SARS-CoV-2 in hospitalized patients: a preliminary matched case-control study.
Hao SR; Yan R; Zhang SY; Lian JS; Cai H; Zhang XL; Zheng L; Jia HY; Hu JH; Yu GD; Gu JQ; Ye CY; Jin CL; Lu YF; Xin JJ; Sheng JF; Yang YD
J Zhejiang Univ Sci B; 2020 Aug.; 21(8):628-636. PubMed ID: 32748578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
